Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).

doi:10.1158/1078-0432.CCR-21-2389

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2022

Nixon Andrew B, Sibley Alexander B, Liu Yingmiao, Hatch Ace J, Jiang Chen, Mulkey Flora, Starr Mark D, Brady John C, Niedzwiecki Donna, Venook Alan P, Baez-Diaz Luis, Lenz Heinz-Josef, O'Neil Bert H, Innocenti Federico, Meyerhardt Jeffrey A, O'Reilly Eileen M, Owzar Kouros, Hurwitz Herbert I

Abstract excerpt

PURPOSE: CALGB 80405 compared the combination of first-line chemotherapy with cetuximab or bevacizumab in the treatment of advanced or metastatic colorectal cancer (mCRC). Although similar clinical outcomes were observed in the cetuximab-chemotherapy group and the bevacizumab-chemotherapy group, biomarkers could identify patients deriving more benefit from either biologic agent. PATIENTS AND METHODS: In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Biomarkers

Share to Cetuximab

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to Fluorouracil

Share to Leucovorin

Source

Open in PubMed Open full text

Identifiers

PMID: 34965954
DOI: 10.1158/1078-0432.CCR-21-2389
PMCID: PMC9240111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).PMID 34965954Read ↗

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.Semantic proximity Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Contribution of plasma levels of VEGF-A and angiopoietin-2 in addition to a genetic variant in KCNAB1 to predict the risk of bevacizumab-induced hypertension.Semantic proximity Read ↗

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal CancerSemantic proximity Read ↗

Biomarkers of Angiogenesis in Colorectal CancerSemantic proximity Read ↗

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.Semantic proximity Read ↗

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-<i>β</i>2 levels in metastatic colorectal cancer patients (Alliance)Semantic proximity Read ↗

Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.Semantic proximity Read ↗

Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).Semantic proximity Read ↗

Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.